Proactive Investors - Run By Investors For Investors

Aegle Therapeutics hopes to treat rare pediatric skin disorder

Aegle Therapeutics CEO Shelley Hartman joined Proactive Investors at the 11th Annual Biotech Showcase in San Francisco. 

The Phase 1/2a ready company isolating extracellular vesicles from allogeneic bone marrow derived mesenchymal stem cells to treat severe dermatological conditions, including burns and epidermolysis bullosa, a rare pediatric connective tissue disorder, and to prevent scarring.

View full AEGLE profile View Profile

Aegle Therapeutics Corp Timeline

Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use